DENVER, July 16, 2009 (GLOBE NEWSWIRE) -- The law firm of Dyer & Berens LLP (www.DyerBerens.com) announced today that it has initiated an investigation concerning losses suffered by certain Matrixx Initiatives, Inc. investors (Nasdaq:MTXX).
The investigation focuses on whether Matrixx, the maker of Zicam products, improperly withheld information from the Food and Drug Administration ("FDA") concerning more than 800 reports relating to the loss of sense of smell associated with the Zicam Cold Remedy intranasal products. In a letter dated June 16, 2007, the FDA informed Matrixx that it concluded that certain Zicam products may pose serious risks to consumers who use them. In response, Matrixx common stock plummeted from approximately $19 per share to less than $7 per share. Thereafter, the company disclosed that the Securities and Exchange Commission had launched an informal inquiry into its conduct.
If you have information relevant to the investigation, or if you believe you were harmed by the conduct described above, you may contact Jeffrey A. Berens, Esq. at 1-888-300-3362 or via email at jeff@dyerberens.com.
The law firm of Dyer & Berens LLP focuses on complex class action litigation on behalf of injured investors throughout the nation. The firm's extensive experience in securities litigation, particularly in cases brought under the Private Securities Litigation Reform Act, has contributed to the recovery of hundreds of millions of dollars for aggrieved investors. For more information about the firm, please go to www.DyerBerens.com.